Aramco’s Prosperity7 Ventures Leads $14M Series B Round for China’s Cispoly
Cispoly, a China-based producer specializing in gynecological tumor detection equipment, has successfully raised over $14 million in a Series B funding round
The funding round was led by Prosperity7 Ventures, the diversified growth fund affiliated with Saudi Arabian energy giant Aramco. Existing investor Sunland Fund also participated in the round.
Focus on Early-Stage Gynecological Tumor Detection: Established in 2020 by Liu Pei, Cispoly focuses on the development of methylation detection tools for early-stage gynecological tumors, including cervical cancer, ovarian cancer, and endometrial cancer. The startup also offers products for women’s reproductive microbiota testing.
Flagship Product Approval and Upcoming Offerings: Cispoly’s flagship product, Ciscer, designed for real-time cervical cancer detection, received approval from China’s National Medical Products Administration in March. The company has additional products in the pipeline, including Cisendo (endometrial cancer screening) currently in clinical trials and Cisova (methylation-based ovarian cancer diagnosis) nearing clinical testing.
Utilizing Funds for R&D and Global Expansion: The Series B funds will be deployed by Cispoly for research and development activities, global expansion initiatives, and expediting product registrations. The startup has initiated research projects in China and plans to extend its presence to Southeast Asia and Europe through collaborations with medical institutions.
Prosperity7 Ventures’ Commitment to Chinese Healthtech: This investment by Prosperity7 Ventures signifies the fund’s continued interest in the Chinese healthtech sector. Notably, the fund has previously participated in series C and D rounds for Fourier Intelligence, a company specializing in exoskeleton robotics products for rehabilitation exercise.
Diverse Investment Portfolio: Prosperity7 Ventures, with its diverse investment portfolio, has demonstrated its commitment to supporting innovation in healthtech. Other investments include a $28.7 million series B round in China’s Jiandanxinli and a $35 million investment in Hong Kong’s Insilico Medicine last year.